Recent research published in JAMA Psychiatry reveals that semaglutide (Ozempic/Wegovy), a popular weight-loss drug targeting GLP-1 hormone, also aids individuals with alcohol addiction. In a controlled study involving 48 individuals with alcohol-use disorder, participants receiving weekly semaglutide injections reported reduced alcohol consumption compared to a placebo group. Although both groups did not alter the number of drinking days, the semaglutide group displayed a significant decrease in overall alcohol intake, suggesting its dual effectiveness in addressing weight management and addiction issues, with FDA support for its health benefits beyond weight loss.
In a trial, semaglutide (Ozempic/Wegovy) showed promise in helping individuals with alcohol addiction reduce cravings and lower their overall alcohol consumption.
The study's unique design involved participants relaxing in a lab resembling a living room, allowing them to drink their favorite alcoholic beverages under observation.
Despite not drinking fewer days per week, those on semaglutide consumed less alcohol overall, indicating its potential utility in treating alcohol-use disorder.
Researchers found significant differences in alcohol intake, highlighting the medication’s ability to assist in managing both weight and addictive behaviors in subjects.
Collection
[
|
...
]